PaxVax launches efforts to develop a vaccine to protect people from being infected by the Zika virus.
PaxVax continues to advance its social mission by researching to develop a Zika vaccine before it spreads to unaffected areas and travelers become affected.
The FDA accepts and grants priority review of the Biologics License Application (BLA) for the PaxVax cholera vaccine.
A new $105 million investment by Cerberus Capital Management helps PaxVax focus on growing its typhoid vaccine business and launching its oral cholera vaccine.
Cerberus Capital Management, a private-equity firm, invests $105 million in PaxVax to alleviate debt and allow the company to focus on the growth of its typhoid vaccine and launch its single-dose oral vaccine for cholera.
With a well-educated workforce, strong business environment, and robust life science market, PaxVax Berna complements the company’s current goals and plan for growth.
PaxVax acquires Crucell Switzerland and saves nearly 80 high-quality manufacturing jobs. Looking ahead, the company plans to increase the site’s production as it brings new vaccines to market.
To promote its typhoid vaccine, PaxVax uses a team of seven to target the Department of Defense, large integrated health networks, universities and large wholesalers and distributers to reach approximately 100,000 vaccinators.
Among CEOs, chief scientists, advocates and other nominees, Dr. Thomas Monath, PaxVax Chief Technology Officer, is named the second most influential person in vaccines by VaccineNation.
When tested against patients given a placebo, the PaxVax oral vaccine for the treatment of cholera was effective both 10 and 90 days after vaccination.
Rochester Clinical Research is among several U.S. sites testing the PaxVax cholera vaccine in preparation for FDA approval to market to Americans traveling to high-risk areas.
PaxVax is changing the future for individuals who want to travel to areas affected with cholera, as its rapid-acting, single-dose oral vaccine enters Phase III clinical trials.